Soft­Bank, Cor­morant lead hefty $210M in­jec­tion for Umo­ja's three-in-one can­cer im­munother­a­py play

Umo­ja Bio­phar­ma has scored some bold back­ers for its grand vi­sion to re­shape can­cer im­munother­a­pies.

The Seat­tle-based biotech is ty­ing the bow around a $210 mil­lion Se­ries B that fea­tures promi­nent crossover play­ers: Soft­Bank Vi­sion Fund 2, Cor­morant As­set Man­age­ment, RTW In­vest­ments, Temasek, Pre­sight Cap­i­tal, Caas Cap­i­tal, and an in­vest­ment fund as­so­ci­at­ed with SVB Leerink. Ex­ecs de­clined an in­ter­view, a move that fits in­to an in­creas­ing­ly com­mon play­book point­ing to an IPO next.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER